A Multi-center, Prospective, Single-arm, Open Label Phase II Study of Chidamide Combined With Chemotherapy in the Treatment of Peripheral T Cell Lymphoma

Fecha de inicio: 1 de noviembre de 2015

Inclusion Criteria: * Pathologically verified peripheral T-cell lymphoma, partial response or stable disease after 3 cycles of CEOP (cyclophosphamide, epirubicin or doxorubicin, vincristine and prednisone) or CEOP(cyclophosphamide,vincristin,epirubicin and prednisone)/IVE (ifosfamide, epirubicin, etoposide)/GDP(Gemcitabine, Cis-platinum, Dexamethasone) * Age ≧16 years, ≦75 years * ECOG (Eastern Cooperative Oncology Group) =0,1,2 * No previous history of malignancy * Radiologically measurable disease * Life expectancy\>6 months * Informed consented Exclusion Criteria: * Active infectious disease requiring general antibiotics, anti-fungal or anti-virus therapy * Lab at enrollment(unless caused by lymphoma) * Neutrophile\<1.5\*10\^9/L * Platelet\<75\*10\^9/L * Hemoglobulin\<90g/L * ALT(alanine aminotransferase) or AST (aspartate aminotransferase ) \>2\*ULN,AKP(alkaline phosphatase) or bilirubin \>1.5\*ULN (upper limit of normal ) * Creatinine\>1.5\*ULN * Other uncontrollable medical condition that may that may interfere the participation of the study * Not able to comply to the protocol for mental or other unknown reasons * Pregnant or lactation * HIV infection